€458.20
Your prediction
Regeneron Pharmaceuticals Inc. Stock
Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Regeneron Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 1.820% | 5.893% | -10.682% | -52.061% | -32.259% | -13.187% | -12.390% |
| Exact Sciences | -0.080% | -3.779% | -3.368% | 16.374% | -14.785% | 29.405% | -38.898% |
| Incyte Corp. | -0.840% | -0.238% | 7.990% | 0.480% | -10.743% | -9.879% | -28.271% |
| Amgen Inc. | -0.600% | 0.353% | 5.817% | -8.024% | 2.016% | 12.376% | 31.943% |
Comments
News
These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025
The Nasdaq-100 market index holds a lot of volatile stocks. Some of its top performers seem overvalued today, while others seem to have room for further growth. The index as a whole rose 9.1% last
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, Eylea, a medicine that treats wet age-related macular degeneration. The therapy is
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
Even though broader equities have been highly volatile this year, it's still a good idea to invest in stocks for a straightforward reason. Holding shares of top companies for five years and beyond